Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PRE 
Prenetics Global Ltd (PRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PRE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -52.39% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 58.89M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 6047 | Beta -0.31 | 52 Weeks Range 2.85 - 6.99 | Updated Date 03/30/2025 |
52 Weeks Range 2.85 - 6.99 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.63 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -183.52% | Operating Margin (TTM) -151.82% |
Management Effectiveness
Return on Assets (TTM) -11.06% | Return on Equity (TTM) -23.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11424817 | Price to Sales(TTM) 1.92 |
Enterprise Value 11424817 | Price to Sales(TTM) 1.92 | ||
Enterprise Value to Revenue 0.45 | Enterprise Value to EBITDA 0.14 | Shares Outstanding 10636300 | Shares Floating 8956477 |
Shares Outstanding 10636300 | Shares Floating 8956477 | ||
Percent Insiders 21.4 | Percent Institutions 13.44 |
Analyst Ratings
Rating 5 | Target Price 9 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Prenetics Global Ltd
Company Overview
History and Background
Prenetics Global Limited, founded in 2013, is a genetic and diagnostic health testing company. It has grown through acquisitions and strategic partnerships to offer a range of testing services.
Core Business Areas
- Prevention & Early Detection: Offers genetic testing and early cancer detection services aimed at proactive health management.
- Personalized Care: Provides personalized treatment plans based on individual genetic profiles, especially in oncology.
- Infectious Disease Diagnostics: Focuses on molecular diagnostics for infectious diseases, including COVID-19 testing.
Leadership and Structure
The company is led by Danny Yeung (CEO). The organizational structure is a mix of functional departments (R&D, Sales, Marketing) and business units focused on specific product lines and geographies.
Top Products and Market Share
Key Offerings
- CircleDNA: A comprehensive at-home DNA test kit. Prenetics estimates they have significant market share, particularly in Asia. Competitors include 23andMe (DNA), AncestryDNA (DNA).
- ColoClear by Circle: A non-invasive stool DNA test for colorectal cancer screening. Revenue data is not publicly available with granular details. Exact market share data is unavailable, however Freenome is a competitor in this space.
- COVID-19 Testing: Molecular diagnostic testing for COVID-19. Competitors include Roche (RHHBY), Abbott (ABT) and QuidelOrtho (QDEL).
Market Dynamics
Industry Overview
The genetic testing and diagnostics industry is experiencing rapid growth due to advancements in technology, increasing awareness of personalized medicine, and rising healthcare expenditure.
Positioning
Prenetics positions itself as a leader in personalized and preventative healthcare through innovative genetic and diagnostic testing solutions. They compete with larger, more established players and smaller, niche providers.
Total Addressable Market (TAM)
The global genetic testing market is projected to reach hundreds of billions of dollars in the coming years. Prenetics is aiming to capture a significant share of this market through its diverse product offerings.
Upturn SWOT Analysis
Strengths
- Innovative product portfolio
- Strong presence in Asia
- Established brand recognition for CircleDNA
- Strategic partnerships
Weaknesses
- Limited profitability
- High marketing expenses
- Dependence on key suppliers
- Relatively small market capitalization
Opportunities
- Expansion into new geographic markets
- Development of new diagnostic tests
- Increased adoption of personalized medicine
- Strategic acquisitions
Threats
- Intense competition
- Regulatory changes
- Data privacy concerns
- Economic downturns
Competitors and Market Share
Key Competitors
- 23andMe (DNA)
- AncestryDNA (DNA)
- Roche (RHHBY)
- Abbott (ABT)
- QuidelOrtho (QDEL)
Competitive Landscape
Prenetics faces competition from established players with larger resources and market share, as well as smaller, niche providers. Prenetics' competitive advantage lies in its innovation, specific product offerings, and its foothold in the Asian market.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Prenetics has demonstrated growth in revenue, driven by increasing adoption of its DNA testing services.
Future Projections: Analyst estimates suggest continued revenue growth, driven by expanding its product offerings and geographic reach, however profitability is still in question.
Recent Initiatives: Recent initiatives include expansion of ColoClear screening, partnerships with health systems, and product development in personalized oncology.
Summary
Prenetics Global Ltd is a growing genetic testing company focused on personalized and preventative healthcare. It is showing revenue growth but is currently unprofitable. The company is challenged with high marketing expenses, a small market capitalization, and competition from industry giants. The focus on product innovation and potential expansion into new markets are crucial for its long-term success.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
DNA
Ginkgo Bioworks Holdings
DNA
Ginkgo Bioworks Holdings
QDEL
Quidel Corporation
QDEL
Quidel Corporation
Sources and Disclaimers
Data Sources:
- Prenetics Global Ltd.'s official website
- Company filings
- Third-party industry reports and analysis.
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prenetics Global Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-05-18 | Co-Founder, Chairperson & CEO Mr. Sheng Wu Yeung | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 320 | Website https://www.prenetics.com |
Full time employees 320 | Website https://www.prenetics.com | ||
Prenetics Global Limited, a health sciences company, focuses on advancing consumer and clinical health. The company's consumer initiatives is led by IM8, a new health and wellness brand. Its prevention arm, CircleDNA, uses next-generation sequencing (NGS) technology to offer comprehensive consumer DNA test. It also develops and commercializes multi-cancer early detection technologies. In addition, the company offers a range of genomic profiling panels tailored for requirements and clinician needs, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests. Further, the company offers ACTLiquid Pro, a sequencing based liquid biopsy assay for pan-solid tumors; ACTMonitor, which provides real time monitoring of drug resistance, treatment response, and cancer recurrence; and ACT Risk, which manages the cancer risk. Additionally, it is involved in the sports distribution activities providing sports nutrition products to fitness facilities. The company operates in Taiwan, Hong Kong, the United Kingdom, and internationally. The company was founded in 2014 and is based in Quarry Bay, Hong Kong and has a presence in the United States.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.